Practice Update - ESC Congress 2017

PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. Editor-in-Chief Douglas Zipes MD Associate Editors Joerg Herrmann MD , Benjamin Scirica MD Advisory Board Deepak Bhatt MDMPH FACC FAHA FSCAI FESC , Peter Libby MD , Paul Thompson MD , James Udelson MD , Ronald Victor MD , Gary Webb MD , Clyde Yancy MDMScMACCFAHAMACP Editorial Contributors Ashish Aggarwal MD , Samer Ajam MD , Jason Garlie MD , John Garner MD PracticeUpdate ® is a registered trademark of Elsevier Inc. 2017 Elsevier Inc. All rights reserved. ABOUT For a complete listing of disclosures for each board member and editorial contributor, please refer to their profile on PracticeUpdate.com PracticeUpdate ’s mission is to help medical professionals navigate the vast array of available literature and focus on the most critical information for their patients and practice. PracticeUpdate Conference Series is a collection of key research from leading international conferences, reviewed by the PracticeUpdate editorial and advisory board, made available in print format. These news highlights and more are also available online at PracticeUpdate.com PracticeUpdate and the PracticeUpdate Conference Series are commercially supported by advertising, sponsorship, and educational grants. Individual access to PracticeUpdate.com is free. Premium content is available to any user who registers with the site. While PracticeUpdate is a commercially-sponsored product, it maintains the highest level of academic rigour, objectivity, and fair balance associated with all Elsevier products. No editorial content is influenced in any way by commercial sponsors or content contributors. DISCLAIMER The PracticeUpdate Conference Series provides highlights of key international conferences for specialist medical professionals. The ideas and opinions expressed in this publication do not necessarily reflect those of the Publisher. Elsevier will not assume responsibility for damages, loss, or claims of any kind arising from or related to the informationcontained in thispublication, includinganyclaimsrelated to the products, drugs, or services mentioned herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Please consult the full current Product Information before prescribing any medication mentioned in this publication. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. This ESC Congress 2017 PracticeUpdate Conference Series is distributed with the support of A. Menarini Australia. The editorial content herein is independently produced by Elsevier with no involvement by A. Menarini Australia. SALES Fleur Gill fleur.gill@elsevier.com Linnea Mitchell-Taverner l.mitchell@elsevier.com PRODUCTION Content was originally published on PracticeUpdate.com Production of this issue was executed by: Editorial Manager A nne Neilson anne.neilson@elsevier.com Editorial Project Manager Carolyn Ng Designer Jana Sokolovskaja ISSN 2208-150X (Print) • ISSN 2208-1518 (Online)

© ESC Congress 2017 – European Society of Cardiology

CONTENTS

4

12

4 The Interleukin-1 β Inhibitor Canakinumab Cuts Cardiovascular Disease and Lung Cancer Risk by Reducing Inflammation – CANTOS Trial 6 Ibuprofen Is Associated with a Rise in Blood Pressure in Patients with Arthritis and Cardiovascular Risk – PRECISION-ABPM Trial 7 Ablation of Atrial Fibrillation Improves Quality of Life More than Drugs – CAPTAF Trial 8 Renal Denervation Lowers Blood Pressure in Hypertensive Patients Not Taking Antihypertensive Medication – SPYRAL HTN-OFF MED Trial 8 Oxygen Therapy Does Not Improve Survival in Patients With Symptoms of MI – DETO2X-AMI 10 Catheter Ablation Improves Outcomes in Patients With Heart Failure and Atrial Fibrillation – CASTLE-AF Trial 11 Apixaban Lowers Stroke Risk in Patients Undergoing Cardioversion for Atrial Fibrillation – EMANATE Trial

12 Two Results of the PURE Study May Be Game Changers in Heart Disease Prevention 14 Risk Factor-Driven Upstream Atrial Fibrillation Therapy Improves Sinus Rhythm Maintenance 14 Women Are Less Likely Than Men to Receive Recommended Statin Doses 16 Underweight is Associated with Highest Mortality and Costs After Cardiac Catheterization 18 Rivaroxaban + Aspirin Is Shown to Improve Outcomes in Patients With Stable Cardiovascular Disease – COMPASS Trial 19 The Gender Gap in Death from Acute Myocardial Infarction is Closing, Particularly in Women Younger than Age 60 20 Screening for Vascular Disease Saves More Lives at Lower Cost than Cancer Screening – VIVA Trial 22 Anacetrapib Reduces Risk of Serious Cardiovascular Events in High-Risk Patients on Statins – REVEAL Trial

ELSEVIER AUSTRALIA ABN 70 001 002 357 475 Victoria Avenue Chatswood NSW 2067 Australia Locked Bag 7500 Chatswood DC NSW 2067 Printed in Australia. EMC081701

ESC Congress 2017 • PRACTICEUPDATE CONFERENCE SERIES 3